Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab Dosing Regimens in Early Symptomatic Alzheimer's Disease
NCT05738486Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Feb 2023; status: active, not recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05738486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738486.